| Name | Auranofin |
| Description | Auranofin (SKF-39162) is an antirheumatic agent, is used to treat rheumatoid arthritis, improves arthritis symptoms including painful or tender and swollen joints and morning stiffness. |
| Cell Research | Auranofin is dissolved in DMSO. Cells are treated with auranofin (0, 50, 100, 200 and 400 nM) for 72 h for the dose-dependent response assay and 100 nM of auranofin is added into the wells for 0, 24, 72 and 120 h for the time-dependent response assay. Control cultures are treated with DMSO. Cell viability is measured by the MTT assay[2]. |
| In vitro | Auranofin, an established rheumatoid arthritis treatment, also shows promise across a spectrum of other conditions such as cancer and neurodegenerative diseases. It triggers apoptosis via a Bax/Bak-dependent pathway by selectively disrupting mitochondrial redox balance and oxidizing Prx3[1]. Furthermore, auranofin hampers SKOV3 cell proliferation and survival in a dose- and time-specific manner, instigating caspase-3 activation, elevating pro-apoptotic Bax and Bim proteins, and diminishing the anti-apoptotic Bcl-2 in SKOV3 cells[2]. This lipophilic gold-based agent, known for its anti-inflammatory and immunosuppressive characteristics, notably impedes cell growth and induces mitochondrial apoptosis in PC3 human prostate cancer cells, with a noteworthy reduction in cell viability at an IC50 of 2.5 µM after 24 hours[3]. |
| In vivo | Prophylactic treatment of adjuvant-induced arthritis rats with auranofin results in a slight reduction in paw edema, a complete normalization of the depressed IL-2 production, and a reduction of the elevated IL-1 production, without effect on the depressed IL-3 production[4]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2.25 mg/mL (3.32 mM), Solution.
DMSO : 252.5 mg/mL (372.15 mM), Sonication is recommended.
|
| Keywords | TrxR | SKF39162 | SKF 39162 | SARS-CoV | SARSCoV | SARS coronavirus | Inhibitor | inhibit | Bacterial | Auranofin |
| Inhibitors Related | Neomycin sulfate | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Hydroxychloroquine | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
United States
